InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,751.07
(
0.90%
)
US TECH 100
19,482.00
(
1.13%
)
Dow Jones
42,352.75
(
0.81%
)
Brent Oil
77.97
(
0.21%
)
Bitcoin
62,323.01
(
2.59%
)
Post# of 13742
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

~MulaGreen~

Send PM Follow Ignore
Followers 1171
Posts 34538
Boards Moderated 0
Alias Born 03/26/2007

~MulaGreen~

Re: ~MulaGreen~ post# 3837

Tuesday, 05/18/2021 8:37:16 AM

Tuesday, May 18, 2021 8:37:16 AM

Post# of 13742
Medolife has been researching Escozine® as a potential treatment for COVID-19 in clinical research programs in both the United States and the DR.
The Company has completed an Investigational New Drug (IND) filing on Escozine® through the US Food and Drug Administration (FDA) and is awaiting a response.
In the DR, and upon approval from the medical ethics committee, it will commence a double-blind placebo human study on Escozine®, which would mark a substantial step forward in Escozine's path toward worldwide registration and adoption.

https://newsfilter.io/a/3216e51dd6b440faffe147f9be46e438

This Answers All The Speculations.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up